GSK to Acquire Nuvalent for $10.6 Billion, Boosting Oncology Pipeline with Late-Stage Lung Cancer Assets
GSK sits 41% above its 52-week low of $35.45.
Summary
GSK is acquiring Nuvalent for $10.6 billion, gaining late-stage oncology assets for lung cancer that are expected to significantly boost future sales and profits.
Key Events · M&A and Partnerships · GSK
-
Acquisition of Nuvalent
GSK will acquire Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on oncology, for an aggregate equity value of $10.6 billion.
-
Strategic Oncology Assets
The acquisition includes two late-stage, potential best-in-class ROS1 and ALK inhibitors (zidesamtinib and neladalkib) for non-small cell lung cancer, both currently under US FDA review for 2026 approvals.
-
Financial Impact
The deal is expected to be accretive to sales and core operating profit in 2027 and core EPS in 2029, with low single-digit percentage dilution to core EPS for 2026-2028.
-
Market Premium
The purchase price of $124 per share represents a 40% premium to Nuvalent's last closing price.
Analysis · GSK · Life Sciences
This acquisition significantly strengthens GSK's oncology pipeline by adding three lung cancer assets, including two late-stage, potential best-in-class inhibitors currently under FDA review. The $10.6 billion deal, representing a substantial portion of GSK's market capitalization, is a major strategic move expected to drive sales and core operating profit growth from 2027, despite minor near-term EPS dilution. It positions GSK for accelerated entry and expansion in the lung cancer market.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 41.8% of the 507 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.39%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GSK was trading at $49.97 on NYSE in the Life Sciences sector, with a market capitalization of approximately $102.3B. The 52-week trading range was $35.45 to $61.70. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.